Global Cell Therapy Manufacturing Market Report and Forecast 2024-2032

Global Cell Therapy Manufacturing Market Outlook

The global cell therapy manufacturing market size was valued at USD 4.24 billion in 2023, driven by the increasing prevalence of chronic diseases and technological advancement in the cell therapies across the globe. The market size is anticipated to grow at a CAGR of 14.7% during the forecast period of 2024-2032 to achieve a value of USD 14.60 billion by 2032.

Cell Therapy: Introduction

The transplantation of human cells, which is performed to treat cells and tissues in the human body, is known as cell therapy. With the help of cell therapy, repairing and replacement of damaged cells and tissues is performed in the human body. In cell therapy, healthy cells are inserted into the body of a person whose body has unhealthy cells and tissues and are in need to be restored or replaced. A variety of diseases can be potentially treated using cell therapy, such as cancer, cardiovascular diseases, neurological disorders, autoimmune disorders, and genetic disorders.

Global Cell Therapy Manufacturing Market Analysis

The increasing advancements in stem-cell research is one of the key factors which are driving the growth of the market. With the help of these advancements, personalized cell therapies would soon become a reality, and some are already under process of development. Additionally, the presence of chimeric antigen receptor T-cell (CAR-T) cell therapy has gained significant popularity in the last few years. The increasing focus on the manufacturing and scalability of the processes is also anticipated to aid the cell therapy manufacturing market expansion. Closed system manufacturing and process optimization are now in focus due to the increasing commercialization of cell therapies.

Global Cell Therapy Manufacturing Market Segmentations

Market Breakup by Therapy Type

• T-Cell Therapies

• Dendritic Cell Therapies

• Tumour Cell Therapies

• Stem Cell Therapies

• Others

Market Breakup by Technology

• Somatic Cell Technology

• Cell Immortalization Technology

• Viral Vector Technology

• Genome Editing Technology

• Cell Plasticity Technology

• 3D Technology

• Others

Market Breakup by Source of Cell

• Autologous Cell

• Allogeneic Cell

Market Breakup by Scale of Operation

• Preclinical

• Clinical

• Commercial

Market Breakup by Applications

• Oncology

• Cardiovascular Diseases

• Orthopaedic Diseases

• Others

Market Breakup by End User

• Pharmaceutical and Biotechnology Companies

• Academic and Research Institutes

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Cell Therapy Manufacturing Market Overview

The increasing prevalence of chronic diseases and technological advancement in cell therapies is primarily driving the cell therapy manufacturing market growth. After undergoing multiple observations and commercial practices, the efficiency and accuracy of mesenchymal stem cells, along with induced pluripotent stem cells, has provided positive responses from healthcare professionals about it. Their belief is that it can perform extensive tissue repair and immunomodulation with efficiency.

Due to the positive feedback, the demand for these cell therapies has increased and is expected to have a steady growth in the future. The educational institutions and research organization, along with key players present in the market, are collaborating with each other to provide and use resources and put them to better use by collaborating. The academical knowledge is used in research and development, which is further used to manufacture better therapies. With the immense potential of cell therapies, the global cell therapy manufacturing market demand has been witnessing steady growth and is expected to grow significantly in the coming years as well.

Global Cell Therapy Manufacturing Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Novartis AG

• F.Hoffmann La Roche AG 

• Gilead Sciences, Inc. 

• Thermo Fischer Scientific, Inc. 

• Catalent, Inc. 

• JSR Life Sciences LLC (KBI Biopharma Inc) 

• Waisman Center (Waisman Biomanufacturing) 

• Cell and Gene Therapy Catapult 

• Merck KGaA 

• Lonza Group 

• Oxford Biomedica Plc 

• WuXi AppTec 

• Charles River Laboratories International Inc. 

• Institut Merieux (ABL Inc.) 

• BioCentriq 

• Centre for Commercialization of Regenerative Medicine (CCRM) 

• Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics) 

• Amgen Inc. 

• Bluebird Bio Inc. 

• Takeda Pharmaceutical Company Limited

Key Highlights of the Report